ALIT vs AVGO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a low Price/Book of 0.39 and a forward P/E of 2.56 suggesting deep value, the company is unprofitable with a staggering -94.23% profit margin and negative ROE of -66.86%. Revenue is declining YoY by 4%, and while recent EPS growth shows a sharp +185.7% YoY increase, this is from a negative base and inconsistent with long-term trends. The stock trades at a steep discount to the $5.07 analyst target, but fundamental deterioration, poor earnings execution (0/4 beats in last 4 quarters), and lack of Altman Z-Score data raise serious sustainability concerns.
Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.
Compare Another Pair
Related Comparisons
ALIT vs AVGO: Head-to-Head Comparison
This page compares Alight, Inc. (ALIT) and Broadcom Inc. (AVGO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.